drugset / Trial / NCT04150835
Xingnaojing for Mild-to-severe Acute Ischemic Stroke
Phase 4
Unknown
1200 enrolled
Dongzhimen Hospital, Beijing
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · collabAnshan Central Hospital · collabBeijing Shuyi Hospital · collabCangzhou Hospital of Integrated Traditional Chinese and Western Medicine · collabFirst Affiliated Hospital of Guangxi Medical University · collabGuangzhou Hospital of Traditional Chinese Medicine · collabHaikou People's Hospital · collabHubei Hospital of Traditional Chinese Medicine · collabHunan Academy of Traditional Chinese Medicine Affiliated Hospital · collabLiling Hospital of Traditional Chinese Medicine · collabLonghua Hospital · collabPeking University Third Hospital · collabPeople's Hospital of Quzhou · collabSecond Affiliated Hospital of Wenzhou Medical University · collabShaanxi Hospital of Traditional Chinese Medicine · collabShandong University of Traditional Chinese Medicine · collabTaizhou Hospital of Traditional Chinese Medicine · collabThe Affiliated Hospital of Changzhi Academy of TCM · collabThe Airport Hospital of Shunyi District Beijing · collabThe First Affiliated Hospital of Anhui University of Traditional Chinese Medicine · collabThe First Affiliated Hospital of Guizhou University of TCM · collabThe First Affiliated Hospital of Henan University of Traditional Chinese Medicine · collabThe First Hospital of Jilin University · collabThe First Hospital of Qiqihar City · collabThe NO.4 People's Hospital of Hengshui · collabThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine · collabThe Second Hospital of Hebei Medical University · collabThe Second People's Hospital of Anhui Province · collabThe Third Affiliated Hospital of Shenzhen University · collabThe Third Hospital of Xi'an City · collabThe Third People's Hospital of Hubei Province · collabTianshui Hospital of Traditional Chinese Medicine · collabYantai Yuhuangding Hospital · collabZhejiang Provincial Hospital of TCM · collabZhejiang Provincial Tongde Hospital · collabZibo Hospital of Traditional Chinese Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the daily living ability of acute ischemic stroke at 90 days.
Timeline
- Start
- 2020-03-19
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xingnaojing | Unknown | 20 ml | Intravenous |